161 related articles for article (PubMed ID: 21212158)
1. Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma.
Kluin-Nelemans HC; van Marwijk Kooy M; Lugtenburg PJ; van Putten WLJ; Luten M; Oudejans J; van Imhoff GW
Ann Oncol; 2011 Jul; 22(7):1595-1600. PubMed ID: 21212158
[TBL] [Abstract][Full Text] [Related]
2. EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma.
Kluin-Nelemans HC; Coenen JL; Boers JE; van Imhoff GW; Rosati S
Blood; 2008 Aug; 112(4):1039-41. PubMed ID: 18502831
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.
Gallamini A; Zaja F; Patti C; Billio A; Specchia MR; Tucci A; Levis A; Manna A; Secondo V; Rigacci L; Pinto A; Iannitto E; Zoli V; Torchio P; Pileri S; Tarella C
Blood; 2007 Oct; 110(7):2316-23. PubMed ID: 17581918
[TBL] [Abstract][Full Text] [Related]
4. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study.
Kim JG; Sohn SK; Chae YS; Cho YY; Yang DH; Lee JJ; Kim HJ; Shin HJ; Chung JS; Cho GJ; Lee WS; Joo YD; Sohn CH; Oh SJ
Cancer Chemother Pharmacol; 2007 Jun; 60(1):129-34. PubMed ID: 17406867
[TBL] [Abstract][Full Text] [Related]
5. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study.
Buckstein R; Fraser G; Cheung M; Kukreti V; Kuruvilla J; Imrie K; Piliotis E; Pond G; Windsor J; Ghorab Z; Shuoprasad K; Turner R; Meyer RM; Pritchard K; Walker S; Levine M; Crump M
Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):18-28.e4. PubMed ID: 26711181
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404).
Ganjoo K; Hong F; Horning SJ; Gascoyne RD; Natkunam Y; Swinnen LJ; Habermann TM; Kahl BS; Advani RH
Leuk Lymphoma; 2014 Apr; 55(4):768-72. PubMed ID: 23786456
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.
Weidmann E; Hess G; Chow KU; Krause SW; Subklewe M; Kruse J; Weisel KC; Soekler M; Kim SZ; Napieralski S; Rech J; Dreyling M; Jäger E; Mitrou PS
Leuk Lymphoma; 2010 Mar; 51(3):447-55. PubMed ID: 20141439
[TBL] [Abstract][Full Text] [Related]
9. CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial.
Binder C; Ziepert M; Pfreundschuh M; Dührsen U; Eimermacher H; Aldaoud A; Rosenwald A; Loeffler M; Schmitz N; Truemper L;
Ann Hematol; 2013 Nov; 92(11):1521-8. PubMed ID: 23978945
[TBL] [Abstract][Full Text] [Related]
10. Effective treatment of a peripheral T-cell lymphoma/lymphoepitheloid cell variant (Lennert's lymphoma) refractory to chemotherapy with the CD-52 antibody alemtuzumab.
Zeitlinger MA; Schmidinger M; Zielinski CC; Chott A; Raderer M
Leuk Lymphoma; 2005 May; 46(5):771-4. PubMed ID: 16019517
[TBL] [Abstract][Full Text] [Related]
11. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
12. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
[TBL] [Abstract][Full Text] [Related]
13. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study.
Dupuis J; Morschhauser F; Ghesquières H; Tilly H; Casasnovas O; Thieblemont C; Ribrag V; Bossard C; Le Bras F; Bachy E; Hivert B; Nicolas-Virelizier E; Jardin F; Bastie JN; Amorim S; Lazarovici J; Martin A; Coiffier B
Lancet Haematol; 2015 Apr; 2(4):e160-5. PubMed ID: 26687958
[TBL] [Abstract][Full Text] [Related]
14. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Gilman P; Lowe A; Kunkel LA; Fisher RI
J Clin Oncol; 2001 Jan; 19(2):389-97. PubMed ID: 11208830
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma.
Wöhrer S; Chott A; Drach J; Püspök A; Hejna M; Hoffmann M; Raderer M
Ann Oncol; 2004 Nov; 15(11):1680-3. PubMed ID: 15520071
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas.
Kim SJ; Shin DY; Kim JS; Yoon DH; Lee WS; Lee H; Do YR; Kang HJ; Eom HS; Ko YH; Lee SH; Yoo HY; Hong M; Suh C; Kim WS
Ann Oncol; 2016 Apr; 27(4):712-8. PubMed ID: 26861608
[TBL] [Abstract][Full Text] [Related]
18. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D
J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
[TBL] [Abstract][Full Text] [Related]
20. A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study.
Foss FM; Sjak-Shie N; Goy A; Jacobsen E; Advani R; Smith MR; Komrokji R; Pendergrass K; Bolejack V
Leuk Lymphoma; 2013 Jul; 54(7):1373-9. PubMed ID: 23278639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
